{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:32:36Z","timestamp":1780533156180,"version":"3.54.1"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T00:00:00Z","timestamp":1581552000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"DOI":"10.3389\/fcimb.2020.00033","type":"journal-article","created":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T08:24:48Z","timestamp":1581582288000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":22,"title":["In vitro Evaluation of Mannosylated Paromomycin-Loaded Solid Lipid Nanoparticles on Acute Toxoplasmosis"],"prefix":"10.3389","volume":"10","author":[{"given":"Mojdeh","family":"Khosravi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanieh","family":"Mohammad Rahimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delaram","family":"Doroud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elnaz Sadat","family":"Mirsamadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamed","family":"Mirjalali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad Reza","family":"Zali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2020,2,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.2217\/nnm-2018-0038","article-title":"Mannosylated thiolated paromomycin-loaded PLGA nanoparticles for the oral therapy of visceral leishmaniasis","volume":"14","author":"Afzal","year":"2019","journal-title":"Nanomedicine"},{"key":"B2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1007\/s10393-019-01405-7","article-title":"The one health approach to toxoplasmosis: epidemiology, control, and prevention strategies","volume":"16","author":"Aguirre","year":"2019","journal-title":"EcoHealth"},{"key":"B3","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1093\/trstmh\/trz082","article-title":"Sero-molecular evaluation of Toxoplasma gondii infection among HIV-positive patients","volume":"113","author":"Ahmadpour","year":"2019","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"key":"B4","doi-asserted-by":"publisher","first-page":"273","DOI":"10.2147\/DDDT.S60973","article-title":"Drugs in development for toxoplasmosis: advances, challenges, and current status","volume":"11","author":"Alday","year":"2017","journal-title":"Drug Des. Dev. Ther."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1000003","DOI":"10.13188\/2325-4653.1000003","article-title":"Exploitation of the macrophage mannose receptor (CD206) in infectious disease diagnostics and therapeutics","volume":"1","author":"Azad","year":"2014","journal-title":"J. Cytol. Mol. Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejps.2018.02.018","article-title":"Nanoemulsion of atovaquone as a promising approach for treatment of acute and chronic toxoplasmosis","volume":"117","author":"Azami","year":"","journal-title":"Eur. J. Pharm. Sci."},{"key":"B7","doi-asserted-by":"publisher","first-page":"7363","DOI":"10.2147\/IJN.S181896","article-title":"Curcumin nanoemulsion as a novel chemical for the treatment of acute and chronic toxoplasmosis in mice","volume":"13","author":"Azami","year":"","journal-title":"Int. J. Nanomed."},{"key":"B8","doi-asserted-by":"publisher","first-page":"00143","DOI":"10.1183\/23120541.00143-2018","article-title":"High frequency of infection of lung cancer patients with the parasite Toxoplasma gondii","volume":"5","author":"Bajnok","year":"2019","journal-title":"ERJ Open Res."},{"key":"B9","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.nano.2019.02.017","article-title":"Nanobiotechnology as an emerging approach to combat malaria: a systematic review","volume":"18","author":"Barabadi","year":"2019","journal-title":"Nanomed. Nanotech. Biol. Med."},{"key":"B10","first-page":"68","article-title":"Patterns of sulfadiazine acute nephrotoxicity","volume":"54","author":"Crespo","year":"2000","journal-title":"Clin. Nephrol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ejps.2017.09.051","article-title":"Atovaquone oral bioavailability enhancement using electrospraying technology","volume":"111","author":"Darade","year":"2018","journal-title":"Eur. J. Pharm. Sci."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1654","DOI":"10.1093\/jac\/dkr147","article-title":"Failure of conventional treatment with pyrimethamine and sulfadiazine for secondary prophylaxis of cerebral toxoplasmosis in a patient with AIDS","volume":"66","author":"Faucher","year":"2011","journal-title":"J. Antimicrob. Chemother."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e90203","DOI":"10.1371\/journal.pone.0090203","article-title":"Toxoplasmosis\u2013a global threat. Correlation of latent toxoplasmosis with specific disease burden in a set of 88 countries","volume":"9","author":"Flegr","year":"2014","journal-title":"PLoS ONE"},{"key":"B14","doi-asserted-by":"publisher","first-page":"e1006523","DOI":"10.1371\/journal.ppat.1006523","article-title":"Cancer therapy in a microbial bottle: uncorking the novel biology of the protozoan Toxoplasma gondii. PLoS Pathog","volume":"13","author":"Fox","year":"2017"},{"key":"B15","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.ejpb.2015.02.008","article-title":"Antigen presenting cell-selective drug delivery by glycan-decorated nanocarriers","volume":"95","author":"Frenz","year":"2015","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B16","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.exppara.2014.05.005","article-title":"Chitosan and silver nanoparticles: promising anti-toxoplasma agents","volume":"143","author":"Gaafar","year":"2014","journal-title":"Exp. Parasitol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1016\/j.nano.2015.06.008","article-title":"Targeted delivery of paromomycin in murine infectious diseases through association to nano lipid systems","volume":"11","author":"Gaspar","year":"2015","journal-title":"Nanomedicine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijpharm.2011.12.037","article-title":"Loading hydrophilic drug in solid lipid media as nanoparticles: statistical modeling of entrapment efficiency and particle size","volume":"424","author":"Ghadiri","year":"2012","journal-title":"Int. J. Pharm."},{"key":"B19","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1007\/s12257-010-0331-5","article-title":"Paromomycin loaded solid lipid nanoparticles: characterization of production parameters","volume":"16","author":"Ghadiri","year":"2011","journal-title":"Biotech. Biopro. Eng."},{"key":"B20","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1111\/pim.12340","article-title":"Enhanced paromomycin efficacy by solid lipid nanoparticle formulation against Leishmania in mice model","volume":"38","author":"Heidari-Kharaji","year":"","journal-title":"Parasite Immunol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"7051","DOI":"10.1007\/s00253-016-7422-y","article-title":"Solid lipid nanoparticle loaded with paromomycin: in vivo efficacy against Leishmania tropica infection in BALB\/c mice model","volume":"100","author":"Heidari-Kharaji","year":"","journal-title":"Appl. Microbiol. Biotechnol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1046\/j.1469-0691.2002.00485.x","article-title":"Toxoplasma gondii: transmission, diagnosis and prevention","volume":"8","author":"Hill","year":"2002","journal-title":"Clin. Microbiol. Infect."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1128\/microbiolspec.PFS-0011-2015","article-title":"Toxoplasma gondii as a parasite in food: analysis and control","volume":"4","author":"Hill","year":"2016","journal-title":"Microbiol. Spectr."},{"key":"B24","doi-asserted-by":"publisher","first-page":"561","DOI":"10.4065\/mcp.2011.0203","article-title":"Antiparasitic therapy","volume":"86","author":"Kappagoda","year":"2011","journal-title":"Mayo Clin. Proc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1702","DOI":"10.1292\/jvms.18-0344","article-title":"How does Toxoplama gondii invade host cells?","volume":"80","author":"Kato","year":"2018","journal-title":"J. Vet. Med. Sci."},{"key":"B26","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1080\/10611860600825159","article-title":"Intracellular macrophage uptake of rifampicin loaded mannosylated dendrimers","volume":"14","author":"Kumar","year":"2006","journal-title":"J. Drug Target"},{"key":"B27","doi-asserted-by":"publisher","first-page":"103","DOI":"10.3389\/fcimb.2019.00103","article-title":"Mechanisms of human innate immune evasion by Toxoplasma gondii","volume":"9","author":"Lima","year":"2019","journal-title":"Front. Cell Infect. Microbiol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1186\/s13071-015-0902-6","article-title":"Diagnosis of toxoplasmosis and typing of Toxoplasma gondii","volume":"8","author":"Liu","year":"2015","journal-title":"Parasit Vectors"},{"key":"B29","doi-asserted-by":"publisher","first-page":"e6","DOI":"10.1111\/j.1432-2277.2010.01173.x","article-title":"Toxoplasma gondii primary infection in renal transplant recipients. Two case reports and literature review","volume":"24","author":"Martina","year":"2011","journal-title":"Transplant. Int."},{"key":"B30","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1093\/jac\/dkl180","article-title":"Antiproliferative activities of two novel quinuclidine inhibitors against Toxoplasma gondii tachyzoites in vitro","volume":"58","author":"Martins-Duarte","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2","DOI":"10.12688\/f1000research.16825.1","article-title":"Case report: ocular toxoplasmosis in a WHIM syndrome immunodeficiency patient","volume":"8","author":"McDermott","year":"2019","journal-title":"F1000Res."},{"key":"B32","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3389\/fcimb.2019.00185","article-title":"Disease tolerance in Toxoplasma infection","volume":"9","author":"Melchor","year":"2019","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1093\/ibd\/izz161","article-title":"Letter to the editor: activated Toxoplasma may attenuate the effect of azathioprine and deteriorate the symptoms in ibd patients via mTORC1manipulation","volume":"25","author":"Mirjalali","year":"2019","journal-title":"Inflamm. Bowel Dis."},{"key":"B34","doi-asserted-by":"publisher","first-page":"25","DOI":"10.3389\/fmicb.2017.00025","article-title":"A systematic review of in vitro and in vivo activities of anti-Toxoplasma drugs and compounds (2006-2016)","volume":"8","author":"Montazeri","year":"2017","journal-title":"Front. Microbiol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1016\/S0140-6736(04)16412-X","article-title":"Toxoplasmosis","volume":"363","author":"Montoya","year":"2004","journal-title":"Lancet."},{"key":"B36","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41409-019-0641-y","article-title":"Features of Toxoplasma gondii reactivation after allogeneic hematopoietic stem-cell transplantation in a high seroprevalence setting","volume":"55","author":"Paccoud","year":"2019","journal-title":"Bone. Marrow. Transplant"},{"key":"B37","first-page":"36","article-title":"Solubility enhancement technique for an anti-malarial drug","volume":"6","author":"Pentewar","year":"2015","journal-title":"Der. Pharm. Sinica"},{"key":"B38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/S0731-7085(96)02044-4","article-title":"Development and validation of a method to extract and quantitate paromomycin and gentamicin from an Aquaphilic cream formulation","volume":"16","author":"Pick","year":"1997","journal-title":"J. Pharm. Biomed. Anal."},{"key":"B39","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1128\/CMR.05013-11","article-title":"Epidemiology of and diagnostic strategies for toxoplasmosis","volume":"25","author":"Robert-Gangneux","year":"2012","journal-title":"Clin. Microbiol. Rev."},{"key":"B40","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s15010-017-1111-3","article-title":"Advances in serological, imaging techniques and molecular diagnosis of Toxoplasma gondii infection","volume":"46","author":"Rostami","year":"2018","journal-title":"Infection"},{"key":"B41","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1007\/s00415-019-09578-5","article-title":"Central nervous system disorders after hematopoietic stem cell transplantation: a prospective study of the infectious diseases working party of EBMT","volume":"267","author":"Schmidt-Hieber","year":"2019","journal-title":"J. Neurol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/S0939-6411(02)00130-3","article-title":"Solvent injection as a new approach for manufacturing lipid nanoparticles\u2013evaluation of the method and process parameters","volume":"55","author":"Schubert","year":"2003","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"B43","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.2147\/IJN.S158736","article-title":"Anti-Toxoplasma activity of various molecular weights and concentrations of chitosan nanoparticles on tachyzoites of RH strain","volume":"13","author":"Teimouri","year":"2018","journal-title":"Int. J. Nanomed."},{"key":"B44","doi-asserted-by":"publisher","first-page":"250","DOI":"10.4103\/aian.AIAN_358_17","article-title":"Restriction fragment length polymorphism-based genotyping of Toxoplasma gondii from autopsy-proven cases of acquired immunodeficiency syndrome-associated cerebral toxoplasmosis","volume":"21","author":"Vijaykumar","year":"2018","journal-title":"Ann. Indian Acad. Neurol."}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00033\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,13]],"date-time":"2020-02-13T08:24:51Z","timestamp":1581582291000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fcimb.2020.00033\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,13]]},"references-count":44,"alternative-id":["10.3389\/fcimb.2020.00033"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2020.00033","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,13]]},"article-number":"33"}}